GlassScriptPhysician profile
Shanika M Eberhardt
NPI 1598357188
$5,393.73
in general payments reported to CMS, 2019-2025
39 companies · $1,400 in 2025
The $1,400 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $741 · 2022: $592 · 2023: $1,203 · 2024: $1,458 · 2025: $1,400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,568 · Education: $493.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,567.83 |
| Education | $492.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $861.82 | 2021-2025 | |
| Incyte Corporation | $475.55 | 2021-2025 | Jakafi, Monjuvi |
| Astrazeneca Pharmaceuticals LP | $345.71 | 2024-2025 | Tagrisso, Imfinzi |
| Genentech USA, INC. | $298.11 | 2021-2023 | Tecentriq |
| Pfizer INC. | $254.67 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $228.07 | 2023-2025 | Alunbrig, Iclusig, Fruzaqla |
| Daiichi Sankyo INC. | $227.50 | 2023-2025 | Enhertu, Injectafer, Datroway |
| Merck Sharp & Dohme LLC | $219.53 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Ipsen Biopharmaceuticals, INC | $203.06 | 2024-2025 | Onivyde |
| Seagen INC. | $199.25 | 2021-2023 | |
| Lilly USA, LLC | $166.83 | 2021-2023 | |
| Gilead Sciences, INC. | $152.17 | 2023-2025 | Trodelvy |
| Beigene USA, INC. | $151.29 | 2023-2024 | Brukinsa |
| Sobi, INC | $144.45 | 2025 | |
| Tersera Therapeutics LLC | $144.07 | 2023-2025 | Zoladex, Xermelo |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shanika Eberhardt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.